Home › NDC Lookup › RxCUI directory › RxCUI 2676760

2.5 ML pegunigalsidase alfa-iwxj 2 MG/ML Injection [Elfabrio] — RxCUI 2676760

Name: 2.5 ML pegunigalsidase alfa-iwxj 2 MG/ML Injection [Elfabrio] (RxCUI 2676760)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2676760 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2676760

Official name2.5 ML pegunigalsidase alfa-iwxj 2 MG/ML Injection [Elfabrio]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as2.5 ML Elfabrio 2 MG/ML Injection; ELFABRIO 5 MG in 2.5 ML Injection; Elfabrio 5 MG per 2.5 ML Injection

FDA products mapped2

Package NDCs mapped4

Reported Medicaid activity (SDUD)79 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How 2.5 ML pegunigalsidase alfa-iwxj 2 MG/ML Injecti... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 2.5 ML pegunigalsidase alfa-iwxj 2 MG/ML Injection [Elfabrio] RxCUI 2676760 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Pegunigalsidase alfa 2637446 IN
- Pegunigalsidase alfa-iwxj 2637445 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Elfabrio 2637458 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Pegunigalsidase alfa Injection 2637455 SCDF
- Pegunigalsidase alfa-iwxj Injection 2648820 SCDFP
- Pegunigalsidase alfa Injectable Product 2637454 SCDG
- Pegunigalsidase alfa-iwxj Injectable Product 2660092 SCDGP
- Pegunigalsidase alfa Injection [Elfabrio] 2637461 SBDF
- Pegunigalsidase alfa-iwxj Injection [Elfabrio] 2656419 SBDFP
- Elfabrio Injectable Product 2637460 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 2.5 ML pegunigalsidase alfa-iwxj 2 MG/ML Injection 2676759 SCD
- Pegunigalsidase alfa-iwxj 2 MG/ML 2637453 SCDC
- Pegunigalsidase alfa-iwxj 2 MG/ML [Elfabrio] 2637459 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

2.5 ML pegunigalsidase alfa-iwxj 2 MG/ML Injection SCD · 2676759
Pegunigalsidase alfa-iwxj 2 MG/ML SCDC · 2637453
Pegunigalsidase alfa Injection SCDF · 2637455
Pegunigalsidase alfa-iwxj Injection SCDFP · 2648820
Pegunigalsidase alfa Injectable Product SCDG · 2637454
Pegunigalsidase alfa-iwxj Injectable Product SCDGP · 2660092

Brand-Name Concepts

Pegunigalsidase alfa-iwxj 2 MG/ML [Elfabrio] SBDC · 2637459
Pegunigalsidase alfa Injection [Elfabrio] SBDF · 2637461
Pegunigalsidase alfa-iwxj Injection [Elfabrio] SBDFP · 2656419
Elfabrio Injectable Product SBDG · 2637460
Elfabrio BN · 2637458

📦 FDA Products & Package NDCs

2 products · 4 package NDCs

4 package NDCs map to RxCUI 2676760 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
10122-0160-02	1 VIAL, SINGLE-DOSE in 1 CARTON (10122-160-02) / 10 mL in 1...	ELFABRIO	Chiesi USA, Inc.	2023-05-23
10122-0160-05	5 VIAL, SINGLE-DOSE in 1 CARTON (10122-160-05) / 10 mL in 1...	ELFABRIO	Chiesi USA, Inc.	2023-05-23
10122-0160-10	10 VIAL, SINGLE-DOSE in 1 CARTON (10122-160-10) / 10 mL in...	ELFABRIO	Chiesi USA, Inc.	2023-05-23
10122-0165-02	1 VIAL, SINGLE-DOSE in 1 CARTON (10122-165-02) / 2.5 mL in...	ELFABRIO	Chiesi USA, Inc.	2024-07-08

Observed labelers: Chiesi USA, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J2508	Pegunigalsidase alfa-iwxj	4	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.